Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases

US5908625A · kind A · utility

Assignee

• Boehringer Mannheim GmbH · DE

Inventors

• Ulrich Kohnert · Habach, DE
• Anne Stern · Penzberg, DE
• Ulrich Martin · Mannheim, DE
• Stephan Fischer · Weilheim, DE

Key dates

• Filing date: Jan 20, 1998
• Grant date: Jun 1, 1999
• Expiry date: Jan 20, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.